In 2012, Topalian et al49 reported results for PD‐1 therapy in nearly 300 people, and an update was provided in 2013.50 Tumors shrunk by about half or more in 31% of those with melanoma, in 29% with kidney cancer, and in 17% with lung cancer. This evidence concerns the gene PDCD1 and melanoma.